Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Drospirenone→

Drospirenone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
67392-87-4
Molecular formula
C24H30O3
Molecular weight
366.5 g/mol
Drug class
Synthetic progestogenprogesterone receptor agonist with antimineralocorticoid and antiandrogenic activity
Mechanism of action
Activates progesterone receptors to suppress gonadotropin secretion and ovulation and also antagonises mineralocorticoid and androgen receptors, contributing to antimineralocorticoid and antiandrogenic effects.
Indications / reported uses
  • Component of combined oral contraceptive products for prevention of pregnancy
  • Used in selected hormone therapy combinations to oppose oestrogen effects on the endometrium; drospirenone-only and combination-product indications differ by jurisdiction

Sources: US DailyMed — Drospirenone-containing products · NLM MeSH — Drospirenone · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Drospirenone Environmental Risk Assessment (ERA) (the Drospirenone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.